Author(s): Dr Amanda Oakley, Waikato Hospital, Hamilton New Zealand, 2008; updated by Dr Geetika Seth, Dermatopathology fellow, University of School of Medicine Boston, USA; Dr Sabrina Sapsford, Dermatology Research Fellow, Te Whatu Ora, Counties Manukau; and Dr Libby Whittaker, DermNet Medical Writer, New Zealand (2023)
What is a baseline series of patch test allergens?
Patch tests are used to identify the cause of allergic contact dermatitis. Standard or baseline series of allergens are recommended for people undergoing patch testing because these include the most common and important allergens that cause dermatitis, and will identify over 70% of culprit allergens. Specific allergens may be added or removed from the series as they become more or less frequent culprits.
Additional allergens may also be tested depending on the patient’s medical and social history, the site of their suspected contact dermatitis or occupation.
The specific standard/baseline series may vary by geographical location due to differences in allergens, medicaments and social practices. The European Baseline Series (EBS) is most commonly used in Europe and elsewhere in the world. Other series include the International Standard, North American Baseline, and American Core Allergen; and series specific to other countries such as Belgium, Finland, Sweden, Hungary, Italy, Korea, Australia, and New Zealand.
An extensive patch test series - the four panels on the left are the standard series
How are the patch tests prepared?
The patch test centre usually orders its allergens from several manufacturers. Most chemicals are mixed in petrolatum and supplied in a syringe. A few chemicals are dissolved in water and supplied in a bottle. The patches consist of hypoallergenic adhesive paper with up to ten chambers. The chambers are made of metal or plastic and are round or square.
The chemicals have been tested to determine the most suitable concentration for testing. If too weak, some people who are allergic to the chemical will not react to the test substance (false negative). If too strong, some people who are not allergic to the chemical will have an irritant reaction (false positive).
A small amount of each petrolatum-based allergen is carefully squeezed into a chamber. Liquid allergen solutions are dropped onto the filter paper placed in the test chamber. Two or three completed patch test panels each with 10-12 allergens applied are fixed to the skin of the upper back. Each patch is carefully numbered or labelled so the allergen in each chamber can be correctly identified.
The patches are generally left in place for 48 hours. The dermatologist will inspect the test site after they have been removed and at least once more, usually 48 hours later.
Baseline series of patch test allergens
Using IQ chambers
Applying liquid for patch testing
Pre-prepared patch test allergens
The Thin-layer Rapid-Use Epicutaneous (T.R.U.E.®) Test series is already prepared; the backing paper is removed and the patches are carefully applied to the patient’s back.
Baseline series of patch test allergens
Baseline series of patch test allergens
Baseline series of patch test allergens
Which chemicals are included in the baseline series?
The chemicals in the baseline series depend on which series is being used. The European Baseline Series (updated 2023) is described below. Most test substances are single compounds but some of the tests are mixtures of closely-related chemicals.
European Baseline Series
The European Baseline Series (EBS) includes 32 allergens (see table below), with another 10 in the extended series (including linalool and limonene hydroperoxides, compositae mix II, diazolidinyl urea, 2-bromo-2-nitropropane-1,3-diol, 2-n-octyl-4-isothiazolin-3-one, sorbitan sesquioleate, and sorbitan monooleate).
European Standard of patch test allergens
Allergen
Concentration % (w/w), in petrolatum (unless stated otherwise)
Surfactant found in many cleansers and cleaning products
T.R.U.E.® Test series
Compared to the European Baseline Series, at the time of writing the T.R.U.E.® Test allergens do not include 2-hydroxyethyl methacrylate, IPPD, sesquiterpene lactone mix, sodium metabisulfite, propolis, fragrance mix II, Lyral, methylisothiazolinone, benzisothiazolinone, textile dye mix, or decyl glucoside. The three test panels comprise 35 allergens, including the following:
The North American Contact Dermatitis Group (NACDG) Baseline Series includes a greater range of allergens (50 baseline allergens, or extended versions with 65 or 80 allergens). It does not include thiomersal. Some of the other allergens in the NACDG series are shown below.
A core allergen series with 80 allergens was released by the American Contact Dermatitis Society (ACDS) in 2013, with subsequent updates in 2017 and 2020. Currently there are 90 allergens listed, available in 9 panels. These are intended to be used as a way to logically extend testing for patients beyond the T.R.U.E.® Test, scaling testing up or down depending on the patient and context. More recent additions in 2020 include:
Allergen
Concentration (%) in petrolatum (unless stated otherwise)
In comparison to the European Baseline Series, the International Standard Series (with 30 allergens) from the International Contact Dermatitis Research Group (ICDRG) does not contain caine mix, sodium metabisulfite, and benzisothiazolinone. The 0.2% methylisothiazolinone (MI) test and 0.01–0.02% methylchloroisothiazolinone + methylisothiazolinone (MCI/MI) tests have been replaced by a single 0.215% MCI/MI test, following a study (Isaksson et al, 2021) showing the 0.215% mix was superior in detecting patients with MCI/MI contact allergy than the other tests combined.
The expanded International Comprehensive Series contains 80 allergens.
The New Zealand Baseline Series
In 2020, patch testing practice in New Zealand was reviewed and the need for national surveillance and identification of relevant allergens was identified. In 2021, the New Zealand Baseline Series (NZBS) was developed by a national panel of dermatologists using a large body of retrospective data. This is the most up-to-date series for the New Zealand population.
There are 30 allergens in the NZBS and another 30 in the extended series, including many from the EBS and the NACDG Baseline Series. Other allergens include:
Allergen
Concentration (%) and vehicle (petrolatum unless stated otherwise)
Patch testing in the paediatric population has been less extensively studied than in the adult population.
In 2017, the US Food and Drug Administration (FDA) approved the T.R.U.E.® Test for use in children aged 6 to 17.
More recently, the Paediatric Baseline Series (PBS) was published in 2018 based on expert consensus at the American Contact Dermatitis Society meeting. The PBS includes 38 allergens, with 2 blank ‘what else’ spots for other allergens as appropriate. It has been found to be superior in picking up positive patch test results than the T.R.U.E.® Test, which unlike the PBS does not include the following important contact allergens in children:
An Australian Paediatric Baseline Series was also subsequently proposed in 2020.
What about other allergens?
There are numerous other chemicals that have been reported to cause contact allergy occasionally. About 15% of patients who have positive reactions at patch testing react to an allergen that is not in the baseline series. These allergens are detected using other series of allergens or individual standardised chemicals that have been selected by the dermatologist based on history taking and potential exposures.
Several series have been developed for patients who present with dermatitis on specific sites of the body or for those with certain occupations (eg, Hairdressing Series, Dental Screening) or other risk factors (eg, Shoe or Cosmetic Series).
Sometimes patients may be strongly positive to an allergen with which, according to their medical and social history, they have little or no contact. In this case, consort contact allergic dermatitis may also be considered.
Bibliography
Chemotechnique Diagnostics. New EBS 2023 Comparison with TRUE Test®. The Patch Tester. March 2023;14:4–7. PDF
Chemotechnique Diagnostics. Patch Test Products and Reference Manual. 2023. PDF
Dupuy E, Miller M, Harter N. What We Have Learned-Milestones in Pediatric Contact Dermatitis. Curr Dermatol Rep. 2022;11(1):1–12. doi: 10.1007/s13671-022-00353-w. Article
Felmingham C, Davenport R, Bala H. Allergic contact dermatitis in children and proposal for an Australian Paediatric Baseline Series. Australas J Dermatol. 2020 Feb;61(1):33–38. doi: 10.1111/ajd.13169. Journal
Isaksson M, Anderson KE, Elsner P, et al. Patch Testing With Methylchloroisothiazolinone/Methylisothiazolinone Using a New Diagnostic Mix-A Multicenter Study From the International Contact Dermatitis Research Group. Dermatitis. 2021;32(4):220–224. doi: 10.1097/DER.0000000000000657. Journal
Sapsford S, Cheng H, Judd L. Patch testing in New Zealand: barriers to evidence-based care. Australas J Dermatol. 2021;62(1):47–50. doi: 10.1111/ajd.13449. Journal
Seine AJ, Baird EA, Chan L, et al. A baseline patch test series for New Zealand. Australas J Dermatol. 2021;62(4):489–495. doi: 10.1111/ajd.13673. Journal
Schalock PC, Dunnick CA, Nedorost S, et al. American Contact Dermatitis Society Core Allergen Series. Dermatitis. 2013;24(1):7–9. doi: 10.1097/DER.0b013e318281d87b. Journal
Schalock PC, Dunnick CA, Nedorost S, et al. American Contact Dermatitis Society Core Allergen Series: 2020 Update. 2020 Sep-Oct;31(5):279-282. doi: 10.1097/DER.0000000000000621. Journal
SmartPractice. AllergEAZE: 2021/2022 Allergen Catalogue. 2022. PDF
Tennstedt D. Patch tests: indications or when testing should be performed? Ann Dermatol Venereol. 2009;136(8-9):579–583. doi: 10.1016/j.annder.2009.06.012. Journal
T.R.U.E. Test® Reference Manual. SmartPractice; 2018. Accessed August 30, 2023. PDF
Wilkinson SM, Gonçalo M, Aerts O, et al. The European baseline series and recommended additions: 2023. 2023 Feb;88(2):87–92. doi: 10.1111/cod.14255. Journal
Yu J, Atwater AR, Brod B, et al. Pediatric Baseline Patch Test Series: Pediatric Contact Dermatitis Workgroup. 2018 Jul/Aug;29(4):206–212. doi: 10.1097/DER.0000000000000385. Journal